A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice

Documenti analoghi

• Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients
  di: Alfonso Piciocchi, et al.
  Pubblicazione: (2024)
• Dasatinib in core‐binding factor acute myeloid leukemia: A promising therapeutic approach
  di: Shyam Srinivasan
  Pubblicazione: (2024)
• Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
  di: Karam Ashouri, et al.
  Pubblicazione: (2024)
• Correction to: Post‐stem cell transplant maintenance in FLT3 mut  acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
  Pubblicazione: (2024)
• CD117 expression predicted FLT3 mutation in T‐cell acute lymphoblastic leukemia
  di: Haijin Wang, et al.
  Pubblicazione: (2024)